文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

树状扫描统计评估疫苗与吉兰-巴雷综合征关联

Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink.
PubMed 文献 · Vaccine · 2026-07-17

研究采用树状扫描统计量、疫苗层级结构和自控风险区间设计,在美国疫苗安全数据链2017-2023年成人中检测疫苗与吉兰-巴雷综合征(GBS)的潜在关联。共识别2584例 incident GBS,仅25%在诊断前0-84天有疫苗接种记录;固定和变化风险窗分析均发现流感疫苗和Janssen COVID-19疫苗等信号,且所有信号疫苗或成分既往均有GBS关联报告。

要点

  • 树状扫描统计可同时评估多组疫苗与GBS的关联,检测组效应。
  • 固定风险窗分析发现流感、Janssen COVID-19、AS01佐剂、肺炎球菌和百白破疫苗信号。
  • 变化风险窗分析仅流感疫苗和Janssen COVID-19疫苗信号持续。

核心结论

  • 树状扫描统计在美国VSD成人中检测到流感疫苗、Janssen COVID-19疫苗等与GBS的统计信号,信号疫苗或成分既往均有GBS关联报告。

研究设计与样本

  • 采用树状扫描统计量、疫苗层级结构和自控风险区间设计,数据来自美国疫苗安全数据链2017-2023年成人。
  • GBS病例通过ICD-10-CM代码G61.0识别,共2584例 incident GBS,40%为≥65岁。
  • 评估诊断前84天内所有疫苗接种,疫苗树包含99个CVX代码,分为7个分支和5个层级。
  • 进行固定和变化风险窗分析,P≤0.05提示可能关联。

主要发现

  • 仅25%的GBS病例在诊断前0-84天有疫苗接种代码。
  • 固定风险窗(风险窗第1-21天,对照窗第43-84天)分析检测到流感疫苗、Ad26.COV2·S(Janssen)COVID-19疫苗、AS01佐剂疫苗(包括重组带状疱疹疫苗)、肺炎球菌疫苗(包括结合疫苗)和百白破疫苗的信号。
  • 变化风险窗分析仅发现流感疫苗和Janssen COVID-19疫苗的信号。
  • 这些疫苗的可归因风险点估计与其他研究大致一致。
  • 所有发出信号的疫苗组或其成分既往均有GBS信号;反之,既往已知与GBS关联的疫苗均未出现阴性结果。

关键数值与推荐

  • GBS病例定义:ICD-10-CM代码G61.0。
  • 风险窗:诊断前第1-21天;对照窗:诊断前第43-84天(固定分析)。
  • 统计显著性阈值:P≤0.05。
  • 疫苗树:99个CVX代码,7个分支,5个层级。

临床怎么用

  • 树状扫描统计可用于疫苗安全性主动监测,尤其适合评估疫苗组与特定结局的关联。
  • 对信号疫苗应结合既往证据和可归因风险进行因果评估,不应仅凭统计信号改变接种建议。
  • 病例发现算法需具有较高特异性,以减少假信号。

局限性

  • 仅基于ICD-10-CM代码识别GBS,可能受编码准确性影响。
  • 仅25%病例有疫苗接种记录,样本代表性或暴露 ascertainment 可能受限。
  • 统计信号不等同于因果关系,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tree-based scan statistics are used to study the safety of specific drugs or vaccines with respect to a broad range of health outcomes. But instead of choosing an exposure of interest and scanning patients' post-exposure outcome data, one can choose an outcome of interest and scan case-patients' pre-diagnosis exposures to vaccines, checking for potential associations. We used tree-based scan statistics, a new hierarchical structure of vaccines, and a self-controlled risk interval design to detect possible associations between vaccines and Guillain-Barré syndrome (GBS) in adults in the U.S. Vaccine Safety Datalink in 2017-2023. Incident GBS cases were identified with ICD-10-CM code G61.0. We assessed all vaccines administered in the 84 days prior to the incident GBS code, using a vaccine "tree" containing 99 CVX codes organized into 7 branches and 5 levels. We conducted both fixed and varying risk-window analyses. P ≤ 0.05 signaled a possible association. There were 2584 incident GBS cases; 40% were ≥ 65 years old. Only 25% had any vaccination code in the preceding 0-84 days. Using a Bernoulli tree-based scan statistic and risk and control windows of Days 1-21 and 43-84 before diagnosis, respectively, statistical signals were detected for influenza vaccines; Ad26.COV2·S (Janssen) COVID-19 vaccine; AS01-adjuvanted vaccines, including recombinant zoster; pneumococcal vaccines, including conjugate; and tetanus-diphtheria-acellular pertussis vaccine. Varying risk-window analysis found signals for influenza and Janssen COVID-19 vaccines. Attributable risk point estimates for these vaccines were in general agreement with other studies. All the vaccine groups that signaled, or their components, have had GBS signals in prior work. Conversely, there are no vaccines with a previously known association with GBS for which no signal was found. Tree-based data-mining holds promise for studying other outcomes suspected of association with vaccination, if case-finding algorithms are relatively specific, and allows detection of effects common to groups of related vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yih WK, Duffy J, Daley MF, et al. Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink. Vaccine. 2026. PMID: 42468225. doi:10.1016/j.vaccine.2026.128949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。